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To the Editor: 
We congratulate Nordanstig and colleagues on the Invasive Revascularization Or Not in 
Intermittent Claudication (IRONIC) trial, which investigated the potential benefit of lower 
extremity revascularisation in patients with stable intermittent claudication (IC).1 This trial 
reported that revascularisation improves quality of life in selected IC patients. Despite the 
substantial achievement of completing this trial, we feel that some caution is required in the 
interpretation of the results. 
First, as the authors point out, the control group did not receive supervised exercise therapy 
as this is not widely available in Europe. Supervised exercise therapy has been shown to 
provide symptom reduction similar to lower extremity revascularisation, and may have 
additional benefits in terms of cardiovascular risk reduction.2 The additional value of 
revascularisation over supervised exercise alone is controversial. Previous small trials have 
reported no quality of life benefit from revascularisation and exercise therapy compared to 
exercise therapy alone although they may have been underpowered to examine this 
comparison.3,4 
Second, the IRONIC trial did not examine the impact of revascularisation on day-to-day 
physical activity which may be assessed using devices such as accelerometers. Greater day-
to-day physical activity in patients receiving invasive treatment in comparison with 
conservative management would suggest the potential for additional benefit in terms of 
cardiovascular risk reduction, supporting the use of revascularisation. 
Finally, additional data may facilitate interpretation of the findings of the IRONIC trial. The 
authors report that patients with bilateral symptoms were included in the current study. 
However the number of patients with bilateral symptoms, and their distribution between 
treatment groups is not reported. Bilateral IC is common and has implications in achieving 
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beneficial results through revascularisation in our opinion. Furthermore, the authors did not 
provide details of the number of patients receiving angiotensin converting enzyme inhibitors 
such as Ramipril which have recently been reported to improve IC symptoms.5 Thus the 
influence of these drugs on the assessed outcome measures is unclear. It is also unclear why 
so many patients remained on cilostazol after revascularisation. Finally, the event-free 
survival was lower in the intervention group (77% vs 88%). We presume that this difference 
was not significant but the trend is concerning. Larger studies and longer follow-up are 
needed to be sure that interventional approaches to IC do not put patients at greater event rate 
risk and to assess the durability of this form of treatment. 
We commend Nordanstig and colleagues for their endeavours to improve the management of 
IC. It is hoped that ongoing work in this area will lead to improvements in both quality of life 
and cardiovascular risk reduction in IC patients. 
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